EPW
CPRX

Evolve Private Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Evolve Private Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$733K Buy
29,617
+1,625
+6% +$38.7K 0.04% 424
2025
Q4 		$653K Buy
+27,992
New +$624K 0.04% 426

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Evolve Private Wealth's CPRX Position: Q1 2026 in Review

Evolve Private Wealth increased its Catalyst Pharmaceutical (CPRX) stake by 5.8% in Q1 2026, buying an estimated $38.7K and bringing the position to 29,617 shares worth $733K. The position accounts for 0.04% of the portfolio, ranked #424.

Evolve Private Wealth first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Evolve Private Wealth held 29,617 shares of Catalyst Pharmaceutical worth $733K as of Q1 2026.
  • Evolve Private Wealth bought 1,625 Catalyst Pharmaceutical shares in Q1 2026, an estimated $38.7K.
  • Catalyst Pharmaceutical made up 0.04% of Evolve Private Wealth's portfolio in Q1 2026, its #424 holding.
  • Evolve Private Wealth first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Evolve Private Wealth's 13F filing for Q1 2026, filed 16 Apr 2026.